<SEC-DOCUMENT>0001821586-25-000021.txt : 20251105
<SEC-HEADER>0001821586-25-000021.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105070058
ACCESSION NUMBER:		0001821586-25-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MoonLake Immunotherapeutics
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39630
		FILM NUMBER:		251451696

	BUSINESS ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		41 41 510 8022

	MAIL ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp
		DATE OF NAME CHANGE:	20200818
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mnlk-20251105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d76f1378-c40a-40d3-89b9-243f877aaccb,g:af4f8952-3bbb-4c48-b987-3fde2ab15cfa,d:f0f6cddc64304124bfa3476707594851-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2025" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlk-20251105</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001821586</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlk-20251105.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-05</xbrli:startDate><xbrli:endDate>2025-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if0f6cddc64304124bfa3476707594851_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">___________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION &#160;13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 5, 2025</ix:nonNumeric></span></div><div style="padding-left:3.55pt;padding-right:3.55pt;text-align:center"><span><br/></span></div><div style="padding-left:3.55pt;padding-right:3.55pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">MOONLAKE IMMUNOTHERAPEUTICS</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:30.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.378%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Cayman Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39630</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-1711963</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">Dorfstrasse 29</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-8">6300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Zug</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-10">Switzerland</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">41</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">415108022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Class A ordinary share, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">MLTX</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02. &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On November&#160;5, 2025, MoonLake Immunotherapeutics (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September&#160;30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Item 2.02 and the press release attached hereto as Exhibit 99.1, insofar as they disclose information regarding the Company&#8217;s results of operation and financial condition for the quarter ended September&#160;30, 2025, are being furnished to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01. Regulation FD Disclosure.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On November 5, 2025, the Company issued a press release announcing results from its Phase 2 clinical trial of Sonelokimab (&#8220;SLK&#8221;) in adult patients with palmoplantar pustulosis (the &#8220;LEDA&#8221; trial), as well as an interim analysis of its Phase 3 clinical trial of SLK in adolescents with hidradenitis suppurativa (the &#8220;VELA-TEEN&#8221; trial). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This Item 7.01 and the press release attached hereto as Exhibit 99.1, are being furnished to the SEC and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01. &#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(d) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">. The following exhibit is being furnished herewith:</span></div><div style="text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Title or Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="moonlake-pressreleasexq320.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="moonlake-pressreleasexq320.htm">November</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="moonlake-pressreleasexq320.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="moonlake-pressreleasexq320.htm">5</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="moonlake-pressreleasexq320.htm">, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.045%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Matthias Bodenstedt</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Matthias Bodenstedt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>moonlake-pressreleasexq320.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i56d007142a3445b8a5eddf88a86f059f_1"></div><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody&#174; Sonelokimab</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefit</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrating the potential and competitive benefit of SLK in these patient populations</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Confirmed a Type B meeting with the U.S. Food and Drug Administration (FDA), scheduled to be held on December 15, 2025, to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application (BLA)</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other clinical trials of SLK progressing well and expected to support a catalyst-rich roadmap over the next 12 months, including data releases from the Phase 2 S-OLARIS trial in Axial Spondyloarthritis (axSpA) and the Phase 3 IZAR trials in Psoriatic Arthritis (PsA)</font></div><div style="margin-bottom:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZUG, Switzerland, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 5, 2025 &#8211; MoonLake Immunotherapeutics (NASDAQ&#58; MLTX) (&#8220;MoonLake&#8221; or the &#8220;Company&#8221;), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the third quarter of 2025.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, MoonLake held cash, cash equivalents and short-term marketable debt securities of $380.5 million. The Company expects its cash, cash equivalents and short-term marketable securities, together with committed capital under a previously announced debt facility with Hercules Capital, to be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2027. Research and development expenses for the quarter ended September&#160;30, 2025, were $60.6 million, compared to $49.8 million in the previous quarter. The increase of $10.8 million was driven by increases in expenses with contract research organizations and contract manufacturing organizations, as well as consulting expenses and personnel-related costs, all to support the further ramp-up of MoonLake's clinical trials and preparations for the anticipated submission of the BLA for sonelokimab in the third quarter of 2026. General and administrative expenses for the quarter ended September&#160;30, 2025 were $10.8 million, similar to the $10.9 million incurred in the previous quarter.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company today also released new data from multiple clinical trials of its Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLK&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Phase 2 LEDA clinical trial in PPP, SLK demonstrated clinically meaningful and statistically significant benefit. Patients treated with SLK achieved a mean percent change from baseline in the Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) of 64% at week 16, and 39% of patients achieved a &#8805;75% reduction in the PPPASI (PPPASI75), suggesting that SLK could provide clinically meaningful improvements in this disease for which there are currently no approved therapies. The safety profile of SLK in the LEDA trial was consistent with previous trials with no new safety signals detected. The Company expects to commence a Phase 3 clinical trial in PPP in Q3 2026.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis of long-term data from MoonLake's Phase 3 clinical trials in adult patients with HS, the VELA-1 and VELA-2 trials, SLK demonstrates continuous clinical improvement and potentially competitive advantages beyond the week 16 primary endpoint. The Company confirmed a Type B meeting with the FDA, which is scheduled to be held on December 15, 2025, to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application (BLA).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis of the VELA-TEEN clinical trial, a Phase 3 study of SLK in adolescent HS patients, showed that 46% of patients achieved a HiSCR75 response at week 16 (n&#61;11). The trial is expected to enroll a total of 30-35 patients and topline results are expected to become available in 2026. The data is expected to be part of MoonLake's BLA submission.</font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A presentation including the new clinical data for SLK is available at https&#58;&#47;&#47;ir.moonlaketx.com.</font></div><div style="margin-bottom:3pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Important upcoming anticipated milestones for MoonLake&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">December 15, 2025&#58; Type B meeting with the FDA (minutes expected within following 30 days)</font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q1 2026&#58; Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q2 2026&#58; 52 weeks data of the VELA-1 and VELA-2 trials in HS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q2 2026&#58; Primary endpoint readout of the Phase 3 IZAR-1 trial in PsA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q2 2026&#58; Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q3 2026&#58; Initiate Phase 3 trial in PPP</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Q3&#47;Q4 2026&#58; Submission of a BLA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">H2 2026&#58; Primary endpoint readout of the Phase 3 IZAR-2 trial in PsA</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Ends-</font></div><div><font><br></font></div><div id="i56d007142a3445b8a5eddf88a86f059f_4"></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About MoonLake Immunotherapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A&#47;A, IL-17A&#47;F, and IL-17F&#47;F dimers that drive inflammation. The Company&#8217;s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis &#8211; conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Nanobodies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nanobodies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Nanobodies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Ablynx, a Sanofi company.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sonelokimab</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonelokimab (M1095) is an investigational &#126;40 kDa humanized Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisting of three VHHs covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A&#47;A, IL-17A&#47;F, and IL-17F&#47;F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonelokimab is being assessed in two lead indications, hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), and the Company is pursuing other indications in dermatology and rheumatology, including adolescent HS, palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For adults with HS, sonelokimab is being assessed in two identical Phase 3 trials, the VELA-1 and VELA-2 trials, using the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. In September 2025, we announced primary endpoint data from the VELA-1 and VELA-2 clinical trials. In the combined VELA program, patients treated with SLK experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p&#60;0.001). In VELA-1, SLK achieved statistical significance for all primary and key secondary endpoints using both pre-specified strategies (HiSCR75, delta to placebo of 17%, p&#60;0.001). In VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p&#61;0.053). From week 16, all patients are expected to continue to receive the 120mg dose of SLK through to 48 weeks, with a last assessment planned at week 52, followed by an open-label extension for up to two years. The safety profile of sonelokimab in the VELA trials was consistent with previous trials with no new safety signals detected.</font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonelokimab is currently undergoing evaluation in the VELA-TEEN Phase 3 trial, which is the first clinical study specifically focused on adolescent patients with moderate-to-severe HS.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For PsA, sonelokimab is being assessed in the Phase 3 trials, IZAR-1 and IZAR-2, following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an ACR50 response compared to those on placebo at week 12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonelokimab is also being assessed in the Phase 2 LEDA trial, which is ongoing for PPP, a debilitating inflammatory skin condition affecting a significant number of patients.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Sonelokimab is being assessed in the ongoing Phase 2 S-OLARIS and P-OLARIS trials for active axSpA and PsA, respectively. Both trials features an innovative design complementing traditional clinical outcomes with cellular imaging techniques.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonelokimab has also been assessed in a randomized, placebo-controlled third-party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical responses (Investigator&#8217;s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index 90&#47;100) were observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021&#59; 397&#58;1564-1575).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an earlier third-party Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019&#59;81&#58;196&#8211;203).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the VELA program</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 VELA program has enrolled over 800 patients across VELA-1 and VELA-2. Both global, randomized, double-blind, and placebo-controlled trials are identical in design evaluating the efficacy and safety of the Nanobody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sonelokimab, administered subcutaneously, in adult patients with active moderate-to-severe hidradenitis suppurativa. Similar to the design of the landmark Phase 2 MIRA trial, the primary endpoint is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75, defined as a &#8805;75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trials also evaluate a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total reduction of &#8805;4, the proportion of patients achieving at least 50% reduction from baseline in Numerical Rating Scale (NRS50) in the Patient&#8217;s Global Assessment of Skin Pain (PGA Skin Pain) and complete resolution of Draining Tunnels (DT100). The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials (also referred to as the primary estimand) is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. The trials compare a single 120mg dose of sonelokimab to placebo with HiSCR75 reading out at week 16. Results of the week 16 data were announced in September 2025. Further details are available under NCT06411899 and NCT06411379 at www.clinicaltrials.gov.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the VELA-TEEN trial</font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 VELA-TEEN trial is an open-label, single-arm trial designed to evaluate sonelokimab 120mg administered subcutaneously once every two weeks (Q2W) until week six and once every four weeks (Q4W) from week eight onwards. The trial aims to enroll 30-35 adolescents, aged 12-17, with moderate-to-severe hidradenitis suppurativa, from U.S. sites experienced in clinical trials and pediatric dermatology. The primary trial phase will be 24 weeks with a primary endpoint evaluating the pharmacokinetics, safety, and tolerability of sonelokimab. VELA-TEEN will also evaluate several secondary endpoints, including the proportion of patients achieving the higher clinical response measure of the Hidradenitis Suppurativa Clinical Response Score (HiSCR) 75, in addition to HiSCR50. Other outcomes are the change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), which includes the quantitative measure of draining tunnels, and the proportion of patients achieving a meaningful reduction of the Children&#8217;s Dermatology Life Quality Index (CDLQI) and the Patients Global Assessment of Skin Pain (PGA Skin Pain). Further details are available under NCT06768671 at www.clinicaltrials.gov.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Hidradenitis Suppurativa</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hidradenitis suppurativa (HS) is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects an estimated 2% of the population, with three times more females affected than males. Real-world data in the United States indicates that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15bn by 2035. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the IZAR Program</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) are global, randomized, double-blind, placebo-controlled Phase 3 trials designed to evaluate the efficacy and safety of sonelokimab compared with placebo in a total of approximately 1,500 adults with active psoriatic arthritis (PsA), with a primary endpoint of superiority to placebo in American College of Rheumatology (ACR) 50 response at Week 16. IZAR-1 is expected to enroll biologic-na&#239;ve patients and include an evaluation of radiographic progression, while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-&#945; inhibitors (TNF-IR) &#8212; reflecting patients commonly seen in clinical practice &#8212; and is the first PsA trial to include a risankizumab active reference arm. Both trials will also assess a range of secondary endpoints reflecting the multiple disease manifestations characteristic of PsA. These include skin and nail outcomes, multidomain outcomes, and patient-reported outcome measures such as pain and quality of life assessments. Further details are available under  NCT06641076 and NCT06641089 at www.clinicaltrials.gov.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Psoriatic Arthritis </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Psoriatic arthritis (PsA) is a chronic, progressive and complex inflammatory disease that manifests across multiple domains, leading to substantial functional impairment and decreased quality of life. The clinical features of PsA are diverse, comprising both musculoskeletal (peripheral arthritis, spondylitis, dactylitis, and enthesitis) and non-musculoskeletal (skin and nail disease) domains. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. Although the exact mechanism of disease is not fully understood, evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the S-OLARIS trial</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-OLARIS is an open-label Phase 2 proof-of-concept trial aiming to investigate sonelokimab 60mg administered subcutaneously in approximately 25 patients with active axial spondyloarthritis (axSpA). The primary endpoint is the change from baseline (CfB) at week 12 in the uptake of 18F-NaF in the sacroiliac joints and spine using PET in combination with MRI imaging. Throughout the trial, several other endpoints will be assessed including established clinical disease activity outcomes (e.g., ASAS), </font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scores related to physical function, spinal mobility, and enthesitis as well as patient reported outcomes. The trial also includes an exploratory peripheral blood and tissue biomarker program.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Axial Spondyloarthritis</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axial Spondyloarthritis (axSpA) typically impacts young people, with diagnosis based on chronic inflammatory back pain lasting more than three months with onset under 45 years of age. Advanced disease can lead to progressive and pathologic bone formation and joint fusion, severely limiting spinal mobility. Global reported prevalence of axSpA ranges from 0.5% to 1.5%. AxSpA can be categorized by disease progression into two subtypes&#58; non-radiographic axSpA and ankylosing spondylitis (AS), also known as radiographic axSpA, which is diagnosed based on radiographic evidence of structural changes to the sacroiliac joints. Patients with axSpA experience fatigue, persistent morning stiffness, and pain that worsens at night and can disrupt sleep. Many patients also face the burden of comorbidities such as psoriatic arthritis and psoriasis. Studies have found elevated IL-17 levels in the blood and synovial fluid of patients with axSpA, and IL-17A and IL-17F are both thought to be key contributors to pathogenesis across the spondyloarthropathies. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the LEDA Trial</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LEDA trial is a Phase 2 trial designed to evaluate the efficacy and safety of sonelokimab 120mg administered subcutaneously in adult patients with palmoplantar pustulosis (PPP). The primary endpoint of the trial is percent change from baseline in Palmoplantar Psoriasis Area and Severity Index (ppPASI) with important secondary endpoints including ppPASI75 (at least 75% improvement in the ppPASI). The LEDA trial features an innovative translational research program using peripheral blood and tissue biomarkers as trial controls. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial design has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 MIRA trial in hidradenitis suppurativa, which identified the optimal dosing and demonstrated the potential of sonelokimab to target deep tissue inflammation effectively. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Palmoplantar Pustulosis</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Palmoplantar Pustulosis (PPP) is characterized by the development of blister-like pustules within erythematous, scaly plaques on the palms and the soles of the feet. PPP typically develops in adulthood, more frequently impacts females. Patients frequently experience significant pain, burning, and itching sensations on the palms and soles of the feet which can be debilitating and impair their ability to work, sleep, or perform other activities of daily living. Currently, the treatment of PPP is challenging with a significant unmet need for novel therapies to reduce the symptom burden for patients. Evidence suggests that activation of the IL-17 pathway has an important role in disease pathophysiology.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains certain &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding&#58; the anticipated timing of clinical trials and timing of the results from those trials, the anticipated timing of filing of a BLA in the United States&#59; outcomes of discussions with regulatory authorities, the efficacy and safety of sonelokimab for the treatment of adult HS, adolescent HS, axSpA, PsA and PPP, including in comparison to existing standards or care or other competing therapies, clinical trials and research and development programs&#59; potential market opportunities for sonelokimab&#59; and MoonLake&#8217;s anticipated cash position. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking </font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements as a result of various risks and uncertainties, which include, without limitation, the risk that interim data analyses conducted prior to database lock and based on a limited number of patients having reached the relevant time point are not consistent with final data, risks and uncertainties associated with MoonLake&#8217;s business in general and limited operating history, difficulty enrolling patients in clinical trials, state and federal healthcare reform measures that could result in reduced demand for MoonLake&#8217;s product candidates and reliance on third parties to conduct and support its preclinical studies and clinical trials and the other risks described in or incorporated by reference into MoonLake&#8217;s Annual Report on Form 10-K for the year ended December</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2024 and subsequent filings with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MoonLake Immunotherapeutics Media &#38; Investors Relations </font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;moonlaketx.com</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ICR Healthcare </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mary-Jane Elliott, Namrata Taak, Ashley Tapp</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; +44 (0) 20 3709 5700</font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoonLake&#64;ICRHealthcare.com</font></div><div style="height:61.74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><div id="i56d007142a3445b8a5eddf88a86f059f_7"></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center;text-indent:0.35pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.326%"><tr><td style="width:1.0%"></td><td style="width:61.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share data)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.67pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">September 30, 2025 (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">June 30, 2025 (Unaudited)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">350,736</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">306,681</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Short-term marketable debt securities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">29,743</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">118,402</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">4,022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">3,409</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">26,714</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">26,989</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total current assets </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">411,215</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">455,481</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">1,911</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">2,251</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">622</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">667</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">587</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">1,697</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">3,120</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">4,615</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total assets </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">414,335</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">460,096</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Liabilities and Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Trade and other payables</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">25,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">17,079&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">21,587</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">8,732</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Short-term portion of operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">1,499</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">1,550</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total current liabilities </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">48,368</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">27,361</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">73,741</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">73,381</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">486</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">836</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Pension liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">549</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">574</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">74,776</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">74,791</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">123,144</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">102,152</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Shareholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 3.77pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Class A Ordinary Shares&#58; $0.0001 par value per share&#59; 500,000,000 shares authorized&#59; 63,704,544 shares issued and outstanding as of September&#160;30, 2025&#59; 63,474,253 shares issued and outstanding as of June&#160;30, 2025</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Class C Ordinary Shares&#58; $0.0001 par value per share&#59; 100,000,000 shares authorized&#59; 526,178 shares issued and outstanding as of September&#160;30, 2025&#59; 729,320 shares issued and outstanding as of June&#160;30, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">689,108</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">683,962</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(400,486)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">(330,757)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.72pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">278</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">520</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">288,906</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">353,731</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">2,285</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:100%">4,213</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">291,191</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">357,944</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">Total liabilities and equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:9.85pt"><font><br></font></div></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">414,335</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:100%">460,096</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div style="padding-right:7.1pt;text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">MOONLAKE IMMUNOTHERAPEUTICS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="margin-bottom:0.1pt;text-align:center;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-right:-15.65pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.609%"><tr><td style="width:1.0%"></td><td style="width:61.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.078%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except share and per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2025</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(60,635)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(49,762)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(10,799)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(10,936)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(71,434)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(60,698)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(71,434)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(60,698)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(3,198)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(2,037)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">4,053</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,779</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Loss before income tax</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(70,579)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(55,956)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:6.4pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(115)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(95)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(70,694)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(56,051)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Of which&#58; net loss attributable to controlling interests shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(69,729)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(55,220)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Of which&#58; net loss attributable to noncontrolling interests shareholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(965)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(831)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:3.25pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities and short-term investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(255)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,908)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial gain on employee benefit plans</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(247)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1,895)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(70,941)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(57,946)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comprehensive loss attributable to controlling interests shareholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(69,972)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt double #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(57,087)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(969)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(859)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:3.25pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of Class A Ordinary Shares, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">63,369,984</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">63,282,728</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Basic and diluted net loss per share attributable to controlling interests shareholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1.10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(0.87)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:84.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:-36pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mnlk-20251105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d76f1378-c40a-40d3-89b9-243f877aaccb,g:af4f8952-3bbb-4c48-b987-3fde2ab15cfa-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlk="http://moonlaketx.com/20251105" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://moonlaketx.com/20251105">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20251105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlk-20251105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://moonlaketx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mnlk-20251105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d76f1378-c40a-40d3-89b9-243f877aaccb,g:af4f8952-3bbb-4c48-b987-3fde2ab15cfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_3338adcd-99be-4e0a-be5d-d4a12253dff3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8cf78ddd-da3a-44fa-9df2-f8cfd140942d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e5b142a0-e3aa-4b83-9224-2add25d52f11_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8d92bfaf-e5e4-4409-b57e-96a04e36c9a9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e0b301a5-c0c9-43ad-9159-a1b79ca189e8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_67564287-2c63-456f-aae5-98381472c7c8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_04f6af8c-c68b-4f23-ad4e-3fd8f9a6915b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6e5be897-cbb7-49aa-829e-fef00b380215_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_5593dca1-d5f0-4e28-bd7b-b6d2350a9933_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d5178df6-8ac6-46c3-bfa2-9495a050a9b7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9199e7c8-35d3-4513-b226-28adfa638721_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c142cf57-1fd7-4b35-b471-d0518a698688_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4ac66070-36a7-44a9-acba-f18d10e2b83b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_02f6986f-f16f-47da-bf55-007349d649f2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_998aa0b4-c80d-4e82-b61e-e6f73744dc58_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d3006640-e5f5-4190-becc-ab6a5dcad383_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_21f92bfe-beea-4f7f-b346-b15e036ce040_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_088fbe14-de4c-493d-8357-046ced0045b9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_009b691c-6ae0-4de1-b37c-c13700a4e0f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6c276409-3c03-41ec-890a-8c088f4c0cc7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_582beb4d-e688-4ea9-a164-e398984ebba2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_57208247-687c-4dc7-bec0-a4e0dd44cb5a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_37ab3045-b173-42e2-867f-744b8fe85a1f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mnlk-20251105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:d76f1378-c40a-40d3-89b9-243f877aaccb,g:af4f8952-3bbb-4c48-b987-3fde2ab15cfa-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://moonlaketx.com/role/Cover" xlink:type="simple" xlink:href="mnlk-20251105.xsd#Cover"/>
  <link:presentationLink xlink:role="http://moonlaketx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cfc74965-b3dc-4c2b-bffb-34b81ade17db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_DocumentType_cfc74965-b3dc-4c2b-bffb-34b81ade17db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c14ab6b9-ae1e-47e8-8ba7-1b3283eb0ba3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_DocumentPeriodEndDate_c14ab6b9-ae1e-47e8-8ba7-1b3283eb0ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_06f8b5f2-406f-4c9c-8d44-d5fad1c1108f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityRegistrantName_06f8b5f2-406f-4c9c-8d44-d5fad1c1108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1d61575d-0e73-496d-a661-75c6fa1f123f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1d61575d-0e73-496d-a661-75c6fa1f123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9f9e253c-d2ed-4c70-8055-0fdaa4f2eec3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityFileNumber_9f9e253c-d2ed-4c70-8055-0fdaa4f2eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a604c2f9-10ab-43d5-bd00-7521d0709a56" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityTaxIdentificationNumber_a604c2f9-10ab-43d5-bd00-7521d0709a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7fd57b4c-9238-4918-88bf-69df8d3f685e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityAddressAddressLine1_7fd57b4c-9238-4918-88bf-69df8d3f685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bd8a289d-9ee8-462b-8c7b-96d5cf8c37b0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityAddressPostalZipCode_bd8a289d-9ee8-462b-8c7b-96d5cf8c37b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a3991238-6f38-4986-aba7-8bffa3e878c5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityAddressCityOrTown_a3991238-6f38-4986-aba7-8bffa3e878c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_30cfc613-3f66-4a86-8624-56084a8b2f43" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityAddressCountry_30cfc613-3f66-4a86-8624-56084a8b2f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_cb2d6f31-5f25-4742-a4e4-022a01f33fd7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_CityAreaCode_cb2d6f31-5f25-4742-a4e4-022a01f33fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_36f4a539-5fd1-4277-81fb-baeb588cded5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_LocalPhoneNumber_36f4a539-5fd1-4277-81fb-baeb588cded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2db12077-76ea-4827-a173-be77319af048" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_WrittenCommunications_2db12077-76ea-4827-a173-be77319af048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_fa14f423-611e-4776-92d0-4b22d5ada80d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_SolicitingMaterial_fa14f423-611e-4776-92d0-4b22d5ada80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_800f7b87-991c-4cd6-8763-5ceaa013a6fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_PreCommencementTenderOffer_800f7b87-991c-4cd6-8763-5ceaa013a6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_166a1869-8ff3-45ff-98bb-fdebfb50eec8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_166a1869-8ff3-45ff-98bb-fdebfb50eec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0662a33a-660f-457a-b8e9-a8dbff58af0c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_Security12bTitle_0662a33a-660f-457a-b8e9-a8dbff58af0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dffc6bfb-a987-4fd8-93c8-76f8df487d76" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_TradingSymbol_dffc6bfb-a987-4fd8-93c8-76f8df487d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f4c81228-5059-4e43-b598-87cb05b470a5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_SecurityExchangeName_f4c81228-5059-4e43-b598-87cb05b470a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_93d1dc28-b43f-4ed9-82cb-e9638e66874f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityEmergingGrowthCompany_93d1dc28-b43f-4ed9-82cb-e9638e66874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f0028fa5-e1e7-415a-94ce-17734e2bf48c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_AmendmentFlag_f0028fa5-e1e7-415a-94ce-17734e2bf48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f58e5408-bdc4-445c-9aa3-9a0e5df6c55e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f1fe80ba-c382-43f5-8931-8ff24ae01e2f" xlink:to="loc_dei_EntityCentralIndexKey_f58e5408-bdc4-445c-9aa3-9a0e5df6c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOONLAKE IMMUNOTHERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1711963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Dorfstrasse 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">415108022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary share, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mnlk-20251105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="mnlk-20251105.htm">mnlk-20251105.htm</File>
    <File>mnlk-20251105.xsd</File>
    <File>mnlk-20251105_lab.xml</File>
    <File>mnlk-20251105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mnlk-20251105.htm": {
   "nsprefix": "mnlk",
   "nsuri": "http://moonlaketx.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "mnlk-20251105.htm"
     ]
    },
    "schema": {
     "local": [
      "mnlk-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mnlk-20251105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnlk-20251105_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://moonlaketx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20251105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnlk-20251105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001821586-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001821586-25-000021-xbrl.zip
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M;DV)74F\DM>-/)X[''DQN\_/R%DLN9%@^^.DR-0_S2E6!I\S]3(B&"H'=#/
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MMJADK$QFOV4CZ#Z41@KQ?\>E_@^OQO\!4$L#!!0    ( !PX95N$Q+S-8 (
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MQ)ZTH^%XV-HVDQ;1[F"^+^J\OC_5^2HZ_Z@SWOU'WL\@4BE5F .>8@:0BF)
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M*- ),_3/B:CVD6X^M]JO=,6^%QIVD/+ *+0 G]=HNU'-.Q&(7@ZTT-:@4B7
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M?(3=.-X=)G9&%!B#Z_8U._KRR=$49H0Y0$I&8(:Y +A$ ?^ WV'H >8'[V#
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MC0I6B?Q:IF YHU%]3VAC7"NJ7S>Q]4D:7<KYE^$MM@=5@(<,WL',,7,F!:8
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M! TBL!0R.$ YTZ0O<![98VA-7<^A\V5H=T4AQ3+C&0<3H^GN![+N)C."3<!
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MV+$7;7^Y.DG\-=?J%/T<\FF$B1_)/FBWHO\>B.=!3#$6W!S90*STT&B=LC+
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M_%$)Y1,9WZ3UH#_%5.( C#<^#$5/+4\*C2#;J"M]HNBN0GV<$S4N @:H5FA
M$H14-"#AY8H>+NFAJ9&(.Z.'5@"+37^ED@.)]Y=-73!!DNV?5_S8H>/*3W3J
M42&X253G)M%5D3K!8ZJ)' LE(C&\6RRJMJ[97GAFAC#3$3<SUW%1>H:4[\+:
M:6R$D!I.(BH]-0,G%,A5_DTV*,6\FXUH9UQ"PC[!?X5$EN>#BU44@E(K)'EB
M]PKS*=6BT@Z6Q$KMJ 4\E2./]\C,7]Q#S5#FN3*[:I89CID*.5/'-P70104W
MR[(5R6E*ZLOX$ *X!&?#NSD\"2%]Z?13&T%IQJ'B95G<@B1S BN>B,[E^>XQ
MGDR<N3/99R&>3.7KD,Q27K#%S2N<#]"6=JB$2SIC34D3^0MMQKN%KU5[M\7O
M8]>>_U+A Q>^I]T__RWM^H5G3,S9PE<H2.>_1*MLX3L_)(#CXO>2819^ &7M
M+(Y,+NG\U^&X:-+W^*7ZCG:AK,U,J[Y#8-29\AAF;+F$%V*6!,H@5-&PB- :
M8AEMGXN$*@I^P8C)W4FN-<\0)3< EG;R6J:1*#J51(95D5A&OXBP9;I-B$P*
MA$0]<FR*72 & &P,A)B X9X<+".L65PRSQS1.S55MF8)B,T,-)?8>XZ'V$?9
MSDWJ\2J[Y/>$.Q0C27X@X81WPT,#%<) G"SY?P3S%>]6"ZG864@9XE3J,[7D
MV554ZK$('Y"NHCT*ZF2(D@KW):Z+.\OJL*P$!-E.L<EY]CRD^-Y BB^SOV0#
M7K0/0/K@>2D87UG"='.E(\4F&1E0",0E@475G<Y$X+U%/2FGYE58#R(:Z?JD
M6?$"W.D,CU<3V'BU[\W$!EWLL(3A<N1; E/+T$M <7,\L@/WFX@P*FMVOFW6
MD#(T^')MZ38&\>);3MJ(;,&T&&#(#LU]V%6R\0L]1@W;IV-)Q %=(9IV&FU4
MQP*RSR0H,H=57"S>DJ8N/7;(;7I%!GH>"$,_@>01[85(2,L"A+-*L2IZ#!!^
M82J@#7%ET$VW'9M@^,)8<QTJ8R8_'UNV4\, X03+U13Z4(*^13LXGFM7Z:BF
M)T4&.(;5R((2JV"#E1HX R&I\)@PS_*#J2_B:R#!4Y@E9;D6YM'SO)BJLF@T
M,.I/2!]#K_P[,9$Q+8B!7XY=5BRJV-UF1XG:>ATE7KZ)1=W01!]+L5Y@>U $
M2#HPH2KLR/F4>.G9-QF._^!/Y!FO>VEN7/K16+HWT:*G+NP^#%$)AU)UL4@.
MM1*>-;4E)FP"^4:XW<AK76[*A*(S()ZR )SK>"E*1[7$)K[$J)"7M&9!BYQ/
MI@*+$:1EZ(6Z._.R^6=7V?_S8S4W,C<08(ZN1LQSFWO%,POII51". 5ER\1Y
M6DG8SY;YIAF)WXEI"_F%?Q 8DP+JPD]V<"M&3H N;6Y[RURPE0:),D,2E,P<
M%)B8S.1$"4P61@D)@(9TM6,15E3+/8T'KF.Y8C7CJ9!X< MF&H0UC[T3O%5V
MO'@<0;7I2KE+L XKR@=#A" 3KOR=< $RQRC.^X6X'(*XY)+BBN?,?]*/)=^!
M"Q$_HX81/XR&69' (^S9!!X\3O8+UC:!OUBG<\@1XHCI\Z_<E3RPE3D-AUL7
MBT[P_EVK<9H_!',?%^?\PU?V.36-=C_,)4<2@RRK_,OT.#O#LL8(/,]+<Q*@
MG7QCFK<:ZX5C%T3GC3F=EG4.-]P5T=;_TVBP(_T8[ I6;^M=UH2E*2NCI[8B
ML#LP2\HKA1R_1PZPO?:1Y.WOGNXT=QHOZC3GSXO7YQ\G#E$_S5).K]:;">G6
MV! W5,:, 9VO/GA(P&6/%D!$A"]75Y<7O7^?L?,O7WZ_O+KY?/:U=WWV^\WY
MA_XZ>^(1Q\'G:5(OHLC+3__#U>7'L\O^V4<&G_I7%^<?>S?PQR^]B][EAS/6
M_WQV=O.\A'@T<VRHS]:^+9E)1!'(1#" >Q%48$E<<QKR$_7AU'9"+'TY<3RB
M+MUTFI]B<[$](KU/_"SW9*==K==:N"TC&&=DJQ?+'5NE'?MC9"_^!E*NTVDM
M_1D(O.%OC5IMHSM7#=9H5=N=QCX-=CW*_DBK)E8.V\]-3>^?W]6_FY.O)[7I
M-S;'[RX?+G;/),[X[G&EZP_*A(X2"?2L$R>"EUFKE3 )B2/R@_P8%+F-I_1^
M(P\M'%,U*/4I"N1?&)L[GM,-DG(KB*(C2;Y;ZU*D7[W::L/["TA):FIAJ_G3
M+<K5=K6YEF!-&\O5=0KA--G1[YX9VQAD3$GT#,1IEY\X_XK!DGZ0+@]L*2PS
M&%''EHH<LV5Q#C;HW%X3M*C6V@]ONXECVR[? 4&P(U(&([-\J1^<]!KLLO09
M4L=A5U\=!XZX,,=F./6M/'\G8WPT%PWI?^7FHF(Y+4%T5$JX(3?-37ZCE9+/
M>#9NVN48MRJ3:M5VK<SLA, ;45\#'_A?L2/.-GX6.?48 NI%ZJU4I/M^*8EJ
MC^.5C#K7'U3F.YMNO:EK[7KKP!<'OLCSA=[26AWC:5;=*GU<<@G:'_M!5(DX
M9OL)$$D1!9L/J)Q)YFMWK:>?X#WLC+"UKM9NU ^4>SSE#*.C-?3:8[:DBG!Y
M/A[GL8I2Y;OR[4[M59FBHONR.,4:9>C.7>5]W/H-3:_5#H3;P(P!B=E]LT;,
M-9Z1 DXQ@F/PO+^#UMW 7FEI;:-QH-Q&E.MV'K7YRJ>I=Z33RQ*L+ YYWU"K
M7BL7LF2[UDXKXH'9D""2MT'D+=,&*J9SPS"TFM$L,67WDZS-IM8H#FW,@9 ,
M 5W8H;Q_I@CYG@3R7R:6OY:P3=+Z+ZU%+WVO8CT]._0,?D IG[$#\WYGK'&5
MU#L)D#V)66P%&X>\))G$)^B'G9'5T+J&42;"[8W!K]6:3\P8/#W0M3.VN0ZP
M_C 272,PY3H5=<X>C\HBL?=I%[8. :^-R-9J'SSND@[X,+4W/;7797M26L?;
MCG/RQ@W.9J==)K+MBZHSM%;W4<KN]<5@M[3_#F'85:2N:T9-WR.ZEF__+HG#
M:JVYX/:6%&C)-^U3$B8/B/PMQ5K+AL@LIN8"(G.;LR_QMC$:6KV>;)R7UKKO
MWQDM_?092:\4\".6X+"%MK6%$@JN C4_GA)EPSPOV5DM7=.[K>TG!DN6.,DL
M'+B8\@#@[>0%=SO*ER\8>P&?L9A7+QS1O#WI&O97[$2SLKB1I7S&&TH:JW)"
M-^6273LPI7[&6P*%W@2J09QH!#DU9YOCLI]H3&UD+>UL5SW:X7B<1[&S>=6:
M6JU3V\RPW\QR3Z9Z8+:WQFQ&6]/;W=TQVUNJO>E95A#S%/^?D?I6>2V$<L8P
MEXA.0]LT>_/&*=?1VO5'U3*^*B,L4UZ,G;/ER53^'*#OJ9NS''G5'28(&]UN
MF0BW+WL3A%I3/\"(2CK@0TW2@S5)&<%Y*$QZAD!Y1ZNW.B4F[%Y2M=8&JA[*
MDO9XF*]2WCY<EE1"'[*4SWA+#LZ%[XV$?X,]D\IDA)=/'113L%W7VHU#'=)F
ME*L_M779'D?]TJWWC*&%<E0G[:XA3^=96B:^^J!?O1!=\R8TXC7W\*2K9.>5
M!JRQ3_NNV3@$]#8A6[MQ".?ML0^V;@U(B;3ZNM&9\FVA8F*W&UJ[O7.E_QJI
MVGW&+L/[L(%+E.5[;>QEU.J:T=AY][Y71U:]IAG-M]:)^+76 !BE/RYFG1&^
M?O[;]3 .4SM,[36';9:<!H>GXXU]%V11^ _JZU2>R$UYGB$ME^?(AJ[-&05G
MXN+U)X9!'+:+,AS7#$/68U<!C,8,9HR829S'SK[7J_!F@TW-@-V9;LS3PQCA
M@NXI:^JZIHO_%U^'S(RCL1_ $&QQ2:NNM?6&UFPTU!5.&"+BEX"^<81'W",A
MF!EB$B YV5# K]4Q?LFS&N".U9KUM9Z%!P'F'[/VX9&'L/A\TZY=AQ7VGV@O
MW3JBK,+FPX;"QGA8V#1K+<UH=YXN:=JUKE:OZ2\O9MYX%N#]NT[-J"U4W1Q(
MMQGIWA*FH =#1BB!Z3(\4:3B>,PRIW@,=9E4U[YD,5N=KF;H.P?0[N-&;'7J
M6K?U=@N'>I853V+7C$!CVGSH6,X!7+<!&8_@:ZW1::USG/N!>//$JX,MUFZV
MG_',]SW:A;*>UI], SY&C,\=9XX'?_,RR?=]X:U:^Z 6-P'XU!Y5K_?ZDNAA
M)DQ+QGK[M"3!VE?8N;/6Z6A=?;.HU8&R*WO--NM:N_Z,V'6]6B_'9EY:5F3!
M18'ONA@#<KR(!SS<?5OC<O/2TN-8.CL_/&X?"=?0:D;];:O3TJO.DC/6$KW9
M-32CN_.:KM=&UGJSK74;CT*X;SWYO)MMZLYU 7W"METB\Y?EN<!!QX&J[X@A
M3KK53C/)??W\TP#(7YBL61/Z)1IW%75_79>#7VL'YFW3:4_Z,^<[GV_3I#EP
MY($C-^'(91W#?XRPIZJ2>QDAFIG*GW$8.</9<G%YN&W5;7(A.HUJK8&:R \I
M0WD2<->,G#M^>N_8T5@N5/9&R9QZ>HLY "Z,H^6WT! =S^9>=%*IMU;JN,R_
MXR#5G2->&03<O*V80_!I3TSWWIR%^;=,'*\R-ZME \KKW7:UR#Y[:(S%2V!Q
M]+FWN)<,?:VM].7JZO*B]^\S=O[ER^^75S>?S[[VKL]^OSG_T%^'<W+#7LTX
M$S,8 :45&\S33CSI-+OD>K7>W"JF9TV:?+BZ_'AVV3_[R.!3_^KB_&/O!O[H
MW\!_OIQ=WO39U2=V=0V4NCF'"UCO$J_\<OWU[#/<=OZ?,W9QU5].OOTAQ-'O
MGAG;3L3MXRTSPV9WY;=?Q6A66\TBXF%]""J"5/20]@.*N>8TY"?JPZE"63L>
M39YN.LVO#[Y@3N_1^\3/4E* W&CI7106TO>1+Y9RI$IR9,[H$;^UC&JKM?QG
MX(Z-?C- CC4VO'/Y:(Q656]O]M@=#;:S[F,+K-GR%0#LH*A@A6,NK89G;W'=
M4;**GG6"Z"?'6B=?[G@L&OMQ""YZJ#'^S>)H^&+&BKSV!(K);#,RUX$D/"(*
M](2 #ACIST&]U7&-<< Y^P+7C4-V!EK'3K&D; $"NG4*[1%9$!G[&(J4;\>7
MHC1IL[C?\\F6E6QPE71Q4BW==YW?><YNCJ4<9OE8OA3;:%7"JUZ"_52LF;_R
MD)N!-28U;/,[[OK3"5CN>W,6SM8C7^O1[4GG!LY9),W=A?G6F^Q12]=:]>:S
M0$4/3+&O3-'H:NU6;1VF*)]T+X7&6(52*J_&^)5[8(*YI#!,>^)X3A@%%&_>
MM26V9 ?M)'._YAXR=*W=[6XF6-\\Y;KUM:H7RB<I2B%]-BO_W9';)\ >_G:<
MOYT!<$NUKY;D&=J&UJ@W=EX5]/H(BS9TMW,06&\M3N7ZX;[$J/9H-SU%3!T(
M>Q!3CQ53<YB;PP%$>S7,\K%5B35JV0,0Y[(D2CD!N]8!91;RR\K7-6,]&7\@
M7)YP-4VOMP_*\8TER:ZHP8%H:: QCY>JX<A^[)R&IC?K![(]EFPMK=U>Y[R7
M\HF&4HB;O0H97/AAR 9\Z >J?0J+S&^[5M*OS\-MZUJSO?N<R^LC;+.I=9N'
ME,PA=+!A\6RKVBB$-7_W8#GM_E#A$25*NV?@4FR?UQ_.4*K^$-#8' U@;(A.
M>]MDZZY%M?*)AE*(F[T"4%SR:/-,Y!,AG(^P=,N#\-QF:X#'TR'3K+($ -#E
MCE2K^SQ0D0-+O4V6:K8TO6D<E-+KLX'I6>M7C%X-V?W8L<;B\ Y/:B]F1E'@
M#&)14A[YK+!58JX5ZJZMPCUJT;EQ=6^KJ[5K^Q91VT]2-YM:K:8?!.3KRT ^
MCX#TEK23?;J,?+Z\W'[NS&[K>0KDWAPA._6# ;C='$+)3EY^4I*@7JTUGS-+
M\#+S/*0!WJ"&7]WW'31X[ 4<!O$WMX4R]STV,8-;+CMH<2L.TDZWX=@/H@JH
M\PEH]3O0Z5BV7S95O@]!\%JS=(I['\AF:%W]4"?P"B,U#YS[%,5FX)@N&YF.
MAQ**3Z:N/^.<#;C'AT[$@#3>SL,N^[>ARG;JTQZ0S%@'45H^45$*\;/*2EKK
M?(Y=%586'#;W7(G-QSQCC^%\R^RBQEJ5#@>J/M)LZAQ0%V\%TOUA.V)J.T<W
ME/ADAN?,E#^2"+L]=F%]Y$6WL5:4],!,!V9Z"'.!9T<=8/NO,.#XR,S+HK9Z
M*;S%\UB,!8?OO(H$6:NK==MK-5X\4/J):(NVIG<.]=ZO,,BY?=&X#&E1LK#>
M?F[$;FOW\+)70<A.<RU"ED_TE!9<4;("S5*#*UYFG@=PQ9L+OQ5+NS_H#VY7
M3!B/.>+,B^D4'7_(/K@FZ/ >NPI@'F8P8WWT84*-#<S0L<1I" Z>B&@?U,YC
MR=ZJ:W7T43J- ^TVH%VM4]/:M772P>63)Z6047M5F/G+O+Q)L=SIJ6CE",.L
M&1#8YR.B7ZYD;]\/B%XSN&Q4C;6J50[,>&#&9V=&O7H(YJVM5\LWX,.5AV5]
MLU<>EO557GE8UE=YY0;+>N"$5WGE85E?Y96TK#]20$8E$XHS$ \F4#*W26^E
MTZC6L!/FU ^=R/'!B>(N';!X>N_8T5AZ,]D;I?^FI[>8 W#4XFCY+31$Q[.Y
M%YU4ZJWIJBQ)]M^!;\_@/^-HXO[\/U!+ 0(4 Q0    ( !PX95M=SQ.SR1
M -)N   1              "  0    !M;FQK+3(P,C4Q,3 U+FAT;5!+ 0(4
M Q0    ( !PX95N$Q+S-8 (  /,&   1              "  ?@0  !M;FQK
M+3(P,C4Q,3 U+GAS9%!+ 0(4 Q0    ( !PX95M?K;.C%@H  "E5   5
M          "  8<3  !M;FQK+3(P,C4Q,3 U7VQA8BYX;6Q02P$"% ,4
M"  <.&5;#B&>$J<&  #",   %0              @ '0'0  ;6YL:RTR,#(U
M,3$P-5]P<F4N>&UL4$L! A0#%     @ '#AE6PN];2[U,P  1-4! !X
M         ( !JB0  &UO;VYL86ME+7!R97-S<F5L96%S97AQ,S(P+FAT;5!+
4!08     !0 % % !  #;6      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>mnlk-20251105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnlk-20251105.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001821586</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">MOONLAKE IMMUNOTHERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39630</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-1711963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">Dorfstrasse 29</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-8">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-10">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-11">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">415108022</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Class A ordinary share, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">MLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
